VivoSim's AI-Enabled Liver Tox Models Achieve >90% Accuracy, Outperforming Rivals
VIVS is trading near its 52-week low of $1.02 (13% above the low).
Summary
VivoSim Labs presented data showing its AI-enabled NAMkind™ Liver and GI platforms achieve over 90% sensitivity and less than 5% false positives in liver toxicity prediction, significantly outperforming traditional animal models. This strong product validation is crucial for the company, which recently completed a dilutive public offering to address its 'going concern' status. The superior accuracy helps pharmaceutical clients avoid costly drug development failures, aligning with the FDA's push for human-relevant alternatives and potentially driving significant market adoption.
At the time of this announcement, VIVS was trading at $1.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $1.02 to $5.30. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.